Intermittent preventive treatment in infancy (IPTi) entails routine administration of antimalarial treatment doses at specified times in at-risk infants. Sulfadoxine-pyrimethamine (SDX/PYR) is a combination that has been used as first-line IPTi. Because of limited pharmacokinetic data and suggestions that higher milligram/ kilogram pediatric doses than recommended should be considered, we assessed SDX/PYR disposition, randomized to conventional (25/1.25 mg/kg of body weight) or double (50/2.5 mg/kg) dose, in 70 Papua New Guinean children aged 2 to 13 months. Blood samples were drawn at baseline, 28 days, and three time points randomly selected for each infant at 4 to 8 h or 2, 5, 7, 14, or 21 days. Plasma SDX, PYR, and N 4 -acetylsulfadoxine (NSX, the principal metabolite of SDX) were assayed by high-performance liquid chromatography (HPLC). Using population modeling incorporating hepatic maturation and cystatin C-based renal function, two-compartment models provided best fits for PYR and SDX/NSX plasma concentration profiles. The area under the plasma concentration-time curve from 0 h to infinity (AUC 0-ؕ ) was greater with the double dose versus the conventional dose of PYR (4,915 versus 2,844 g/day/liter) and SDX (2,434 versus 1,460 mg/day/liter). There was a 32% reduction in SDX relative bioavailability with the double dose but no evidence of dose-dependent metabolism. Terminal elimination half-lives (15.6 days for PYR, 9.1 days for SDX) were longer than previously reported. Both doses were well tolerated without changes in hemoglobin or hepatorenal function. Five children in the conventional and three in the double-dose group developed malaria during follow-up. These data support the potential use of double-dose SDX/PYR in infancy, but further studies should examine the influence of hepatorenal maturation in very young infants.Intermittent preventive treatment in infancy (IPTi) is a strategy in which infants in areas in which malaria is endemic are given treatment doses of antimalarial drugs at specified times, regardless of clinical and parasitologic status. Because of its availability, tolerability, and relatively low cost, sulfadoxinepyrimethamine (SDX/PYR) has been used as a first-line treatment in IPTi programs, especially in Africa. A recent review of safety and efficacy data from six trials conducted from 1999 to 2007 revealed that, despite the emergence of molecular markers of parasite resistance, SDX/PYR IPTi reduced clinical malaria and malaria-related hospital admissions by about onethird and reduced anemia in the first year of life by 15% (23). The duration of effective antimalarial prophylaxis after a dose of SDX/PYR is 4 to 6 weeks (9, 17).There is evidence that the efficacy of SDX/PYR IPTi is dose dependent. When given as a fixed dose (27), efficacy declines with age as lower doses (milligrams/kilogram of body weight) are taken (9). In addition, studies of older children aged 2 to 5 years with falciparum malaria have found higher clearance rates and larger apparent volumes of distribution for...